{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T12:20:30Z","timestamp":1783426830140,"version":"3.54.6"},"reference-count":180,"publisher":"IMR Press","issue":"2","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012190","name":"Ministry of Science and Higher Education of the Russian Federation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100012190","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Front. Biosci. (Elite Ed)"],"abstract":"<jats:p>Since the discovery of penicillin in 1928, more than a thousand antibiotics have been introduced into medical practice. Initially, the introduction of antibiotics revolutionized the treatment of infectious diseases. However, as antibiotics have been used repeatedly, scientists and clinicians have observed serious adverse consequences, most notably the emergence of bacterial resistance to antimicrobial agents. Of particular concern are multidrug-resistant pathogens, which are resistant to multiple antibiotic classes. As of 2024, antibiotic-resistant bacteria are directly responsible for approximately 1.27 million deaths worldwide. Thus, in response, possible new antibacterial agents are under investigation, including bacteriophages and the associated bacteriolytic enzymes. According to the World Health Organization (WHO), phage-based drugs are leading nonclassical antibiotics currently in clinical trials. Meanwhile, endolysins, as bacteriolytic phage enzymes, have emerged as promising antibacterial agents. This study reviews the key achievements and mechanisms of action of bacteriophage endolysins against bacterial infections, including biofilms, and discusses the therapeutic potential of endolysins in combating antibiotic resistance. Finally, the combined use of endolysins with other biomolecules and the application of artificial intelligence to address antimicrobial-resistant infections are also discussed.<\/jats:p>","DOI":"10.31083\/fbe44070","type":"journal-article","created":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T12:01:18Z","timestamp":1783425678000},"source":"Crossref","is-referenced-by-count":0,"title":["Endolysins and Their Potential in Combating Bacterial Multidrug Resistance"],"prefix":"10.31083","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0541-0020","authenticated-orcid":true,"given":"Olga I.","family":"Guliy","sequence":"first","affiliation":[{"name":"Institute of Biochemistry and Physiology of Plants and Microorganisms \u2013 Subdivision of the Federal State Budgetary Research Institution Saratov Federal Scientific Centre of the Russian Academy of Sciences (IBPPM RAS), 410049 Saratov, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0665-1846","authenticated-orcid":true,"given":"Olga A.","family":"Karavaeva","sequence":"additional","affiliation":[{"name":"Institute of Biochemistry and Physiology of Plants and Microorganisms \u2013 Subdivision of the Federal State Budgetary Research Institution Saratov Federal Scientific Centre of the Russian Academy of Sciences (IBPPM RAS), 410049 Saratov, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"16242","published-online":{"date-parts":[[2026,6,1]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet (London, England). 2022; 399: 629\u2013655.","DOI":"10.1016\/S0140-6736(21)02724-0"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"GBD 2019 Antimicrobial Resistance Collaborators. Global mortality associated with 33 bacterial pathogens in 2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet (London, England). 2022; 400: 2221\u20132248.","DOI":"10.1016\/S0140-6736(22)02185-7"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Ho CS, Wong CTH, Aung TT, Lakshminarayanan R, Mehta JS, Rauz S, et al. Antimicrobial resistance: a concise update. The Lancet. Microbe. 2025; 6: 100947.","DOI":"10.1016\/j.lanmic.2024.07.010"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"Zheng T, Zhang C. Engineering strategies and challenges of endolysin as an antibacterial agent against Gram-negative bacteria. Microbial Biotechnology. 2024; 17: e14465.","DOI":"10.1111\/1751-7915.14465"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"Uchechukwu CF, Shonekan A. Current status of clinical trials for phage therapy. Journal of Medical Microbiology. 2024; 73: 001895.","DOI":"10.1099\/jmm.0.001895"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Hitchcock NM, Devequi Gomes Nunes D, Shiach J, Valeria Saraiva Hodel K, Dantas Viana Barbosa J, Alencar Pereira Rodrigues L, et al. Current clinical landscape and global potential of bacteriophage therapy. Viruses. 2023; 15: 1020.","DOI":"10.3390\/v15041020"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Gon\u00e7alves T, Marques AT, Manageiro V, Tanoeiro L, Vital JS, Duarte A, et al. Antimicrobial activity of prophage endolysins against critical Enterobacteriaceae antibiotic-resistant bacteria. International Journal of Pharmaceutics. 2024; 651: 123758.","DOI":"10.1016\/j.ijpharm.2023.123758"},{"key":"ref8","unstructured":"World Health Organization. Antibacterial agents in clinical development: an analysis of the antibacterial clinical development pipeline, including tuberculosis. Geneva: World Health Organization. 2017 (WHO\/EMP\/IAU\/2017.12). Available at: http:\/\/www.jstor.org\/stable\/resrep35853.1 (Accessed: 26 August 2025)."},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Guliy OI, Evstigneeva SS, Karavaeva OA. Antimicrobial resistance and current methods for its detection. Frontiers in Bioscience (Elite Edition). 2023; 15: 19.","DOI":"10.31083\/j.fbe1503019"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Catalano A, Iacopetta D, Ceramella J, Scumaci D, Giuzio F, Saturnino C, et al. Multidrug resistance (MDR): A widespread phenomenon in pharmacological therapies. Molecules (Basel, Switzerland). 2022; 27: 616.","DOI":"10.3390\/molecules27030616"},{"key":"ref11","unstructured":"Ding P, Gao Y, Wang J, Xiang H, Zhang C, Wang L, et al. Progress and challenges of multidrug resistance proteins in diseases. American Journal of Cancer Research. 2022; 12: 4483\u20134501."},{"key":"ref12","unstructured":"World Health Organization. WHO Bacterial Priority Pathogens List, 2024: bacterial pathogens of public health importance to guide research, development and strategies to prevent and control antimicrobial resistance. World Health Organization: Geneva. 2024."},{"key":"ref13","unstructured":"Antimicrobial resistance surveillance in Europe 2023 - 2021 data. Stockholm: European Centre for Disease Prevention and Control and World Health Organization. 2023."},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"Bardi T, Pintado V, Gomez-Rojo M, Escudero-Sanchez R, Azzam Lopez A, Diez-Remesal Y, et al. Nosocomial infections associated to COVID-19 in the intensive care unit: clinical characteristics and outcome. European Journal of Clinical Microbiology & Infectious Diseases: Official Publication of the European Society of Clinical Microbiology. 2021; 40: 495\u2013502.","DOI":"10.1007\/s10096-020-04142-w"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"Pasero D, Cossu AP, Terragni P. Multi-drug resistance bacterial infections in critically Ill patients admitted with COVID-19. Microorganisms. 2021; 9: 1773.","DOI":"10.3390\/microorganisms9081773"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"Giacobbe DR, Labate L, Tutino S, Baldi F, Russo C, Robba C, et al. Enterococcal bloodstream infections in critically ill patients with COVID-19: a case series. Annals of Medicine. 2021; 53: 1779\u20131786.","DOI":"10.1080\/07853890.2021.1988695"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"Amarsy R, Trystram D, Cambau E, Monteil C, Fournier S, Oliary J, et al. Surging bloodstream infections and antimicrobial resistance during the first wave of COVID-19: a study in a large multihospital institution in the Paris region. International Journal of Infectious Diseases: IJID: Official Publication of the International Society for Infectious Diseases. 2022; 114: 90\u201396.","DOI":"10.1016\/j.ijid.2021.10.034"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"Tannh\u00e4user R, Nickel O, Lindner M, Bethge A, Wolf J, Borte S, et al. Bacterial contamination of the smartphones of healthcare workers in a German tertiary-care hospital before and during the COVID-19 pandemic. American Journal of Infection Control. 2022; 50: 414\u2013419.","DOI":"10.1016\/j.ajic.2021.09.025"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"Penesyan A, Nagy SS, Kjelleberg S, Gillings MR, Paulsen IT. Rapid microevolution of biofilm cells in response to antibiotics. NPJ Biofilms and Microbiomes. 2019; 5: 34.","DOI":"10.1038\/s41522-019-0108-3"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"Bagge N, Ciofu O, Skovgaard LT, H\u00f8iby N. Rapid development in vitro and in vivo of resistance to ceftazidime in biofilm-growing Pseudomonas aeruginosa due to chromosomal beta-lactamase. APMIS: Acta Pathologica, Microbiologica, et Immunologica Scandinavica. 2000; 108: 589\u2013600.","DOI":"10.1034\/j.1600-0463.2000.d01-102.x"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"Jamal M, Ahmad W, Andleeb S, Jalil F, Imran M, Nawaz MA, et al. Bacterial biofilm and associated infections. Journal of the Chinese Medical Association: JCMA. 2018; 81: 7\u201311.","DOI":"10.1016\/j.jcma.2017.07.012"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"Donlan RM, Costerton JW. Biofilms: survival mechanisms of clinically relevant microorganisms. Clinical Microbiology Reviews. 2002; 15: 167\u2013193.","DOI":"10.1128\/CMR.15.2.167-193.2002"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"Algburi A, Comito N, Kashtanov D, Dicks LMT, Chikindas ML. Control of biofilm formation: Antibiotics and beyond. Applied and Environmental Microbiology. 2017; 83: e02508-16.","DOI":"10.1128\/AEM.02508-16"},{"key":"ref24","unstructured":"NIH Guide: Research on Microbial Biofilms. 2002. Available at: https:\/\/grants.nih.gov\/grants\/guide\/pa-files\/pa-03-047.html (Accessed: 18 June 2025)."},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"Agyeman WY, Bisht A, Gopinath A, Cheema AH, Chaludiya K, Khalid M, et al. A Systematic review of antibiotic resistance trends and treatment options for hospital-acquired multidrug-resistant infections. Cureus. 2022; 14: e29956.","DOI":"10.7759\/cureus.29956"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"Biswas S, Raoult D, Rolain JM. A bioinformatic approach to understanding antibiotic resistance in intracellular bacteria through whole genome analysis. International Journal of Antimicrobial Agents. 2008; 32: 207\u2013220.","DOI":"10.1016\/j.ijantimicag.2008.03.017"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"Courvalin P. Vancomycin resistance in gram-positive cocci. Clinical Infectious Diseases: an Official Publication of the Infectious Diseases Society of America. 2006; 42: S25\u2013S34.","DOI":"10.1086\/491711"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"Nikaido H. Multidrug resistance in bacteria. Annual Review of Biochemistry. 2009; 78: 119\u2013146.","DOI":"10.1146\/annurev.biochem.78.082907.145923"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"Ramirez MS, Tolmasky ME. Aminoglycoside modifying enzymes. Drug Resistance Updates: Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy. 2010; 13: 151\u2013171.","DOI":"10.1016\/j.drup.2010.08.003"},{"key":"ref30","doi-asserted-by":"publisher","unstructured":"Singh MK, Dominy BN. The evolution of cefotaximase activity in the TEM \u03b2-lactamase. Journal of Molecular Biology. 2012; 415: 205\u2013220.","DOI":"10.1016\/j.jmb.2011.10.041"},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"Alekshun MN, Levy SB. Molecular mechanisms of antibacterial multidrug resistance. Cell. 2007; 128: 1037\u20131050.","DOI":"10.1016\/j.cell.2007.03.004"},{"key":"ref32","doi-asserted-by":"publisher","unstructured":"Santajit S, Indrawattana N. Mechanisms of antimicrobial resistance in ESKAPE pathogens. BioMed Research International. 2016; 2016: 2475067.","DOI":"10.1155\/2016\/2475067"},{"key":"ref33","doi-asserted-by":"publisher","unstructured":"Guliy OI, Evstigneeva SS, Bunin VD, Fedonenko YP. Chapter 3 - The role of biofilms and multidrug resistance in wound infections. In Barabadi H, Saravanan M, Mostafavi E, Vahidi H (eds.) Bioengineered Nanomaterials for Wound Healing and Infection Control (pp. 57\u2013114). Woodhead Publishing Series in Biomaterials: USA\/UK. 2023.","DOI":"10.1016\/B978-0-323-95376-4.00001-0"},{"key":"ref34","doi-asserted-by":"publisher","unstructured":"Guliy OI, Evstigneeva SS. Bacterial communities and their role in bacterial infections. Frontiers in Bioscience (Elite Edition). 2024; 16: 36.","DOI":"10.31083\/j.fbe1604036"},{"key":"ref35","doi-asserted-by":"publisher","unstructured":"Walsh C. Molecular mechanisms that confer antibacterial drug resistance. Nature. 2000; 406: 775\u2013781.","DOI":"10.1038\/35021219"},{"key":"ref36","doi-asserted-by":"publisher","unstructured":"Wright GD. Molecular mechanisms of antibiotic resistance. Chemical Communications (Cambridge, England). 2011; 47: 4055\u20134061.","DOI":"10.1039\/c0cc05111j"},{"key":"ref37","doi-asserted-by":"publisher","unstructured":"Reynoso EC, Laschi S, Palchetti I, Torres E. Advances in antimicrobial resistance monitoring using sensors and biosensors: a review. Chemosensors. 2021; 9: 232.","DOI":"10.3390\/chemosensors9080232"},{"key":"ref38","doi-asserted-by":"publisher","unstructured":"Jacob F, Fuerst CR. The mechanism of lysis by phage studied with defective lysogenic bacteria. Journal of General Microbiology. 1958; 18: 518\u2013526.","DOI":"10.1099\/00221287-18-2-518"},{"key":"ref39","doi-asserted-by":"publisher","unstructured":"Abdelrahman F, Easwaran M, Daramola OI, Ragab S, Lynch S, Oduselu TJ, et al. Phage-encoded endolysins. Antibiotics (Basel, Switzerland). 2021; 10: 124.","DOI":"10.3390\/antibiotics10020124"},{"key":"ref40","doi-asserted-by":"publisher","unstructured":"Guliy OI, Evstigneeva SS. Bacteria- and phage-derived proteins in phage infection. Frontiers in Bioscience (Landmark Edition). 2025; 30: 24478.","DOI":"10.31083\/FBL24478"},{"key":"ref41","doi-asserted-by":"publisher","unstructured":"Liu H, Hu Z, Li M, Yang Y, Lu S, Rao X. Therapeutic potential of bacteriophage endolysins for infections caused by Gram-positive bacteria. Journal of Biomedical Science. 2023; 30: 29.","DOI":"10.1186\/s12929-023-00919-1"},{"key":"ref42","doi-asserted-by":"publisher","unstructured":"Parisien A, Allain B, Zhang J, Mandeville R, Lan CQ. Novel alternatives to antibiotics: bacteriophages, bacterial cell wall hydrolases, and antimicrobial peptides. Journal of Applied Microbiology. 2008; 104: 1\u201313.","DOI":"10.1111\/j.1365-2672.2007.03498.x"},{"key":"ref43","doi-asserted-by":"publisher","unstructured":"Bernhardt TG, Wang IN, Struck DK, Young R. Breaking free: \u201cprotein antibiotics\u201d and phage lysis. Research in Microbiology. 2002; 153: 493\u2013501.","DOI":"10.1016\/s0923-2508(02)01330-x"},{"key":"ref44","doi-asserted-by":"publisher","unstructured":"Al-Wrafy F, Brzozowska E, G\u00f3rska S, Drab M, Strus M, Gamian A. Identification and characterization of phage protein and its activity against two strains of multidrug-resistant Pseudomonas aeruginosa. Scientific Reports. 2019; 9: 13487.","DOI":"10.1038\/s41598-019-50030-5"},{"key":"ref45","doi-asserted-by":"publisher","unstructured":"Young R. Phage lysis: three steps, three choices, one outcome. Journal of Microbiology (Seoul, Korea). 2014; 52: 243\u2013258.","DOI":"10.1007\/s12275-014-4087-z"},{"key":"ref46","doi-asserted-by":"publisher","unstructured":"Rajaure M, Berry J, Kongari R, Cahill J, Young R. Membrane fusion during phage lysis. Proceedings of the National Academy of Sciences of the United States of America. 2015; 112: 5497\u20135502.","DOI":"10.1073\/pnas.1420588112"},{"key":"ref47","doi-asserted-by":"publisher","unstructured":"Roach DR, Donovan DM. Antimicrobial bacteriophage-derived proteins and therapeutic applications. Bacteriophage. 2015; 5: e1062590.","DOI":"10.1080\/21597081.2015.1062590"},{"key":"ref48","doi-asserted-by":"publisher","unstructured":"Fischetti VA. Bacteriophage lytic enzymes: novel anti-infectives. Trends in Microbiology. 2005; 13: 491\u2013496.","DOI":"10.1016\/j.tim.2005.08.007"},{"key":"ref49","doi-asserted-by":"publisher","unstructured":"Nelson DC, Schmelcher M, Rodriguez-Rubio L, Klumpp J, Pritchard DG, Dong S, et al. Endolysins as antimicrobials. Advances in Virus Research. 2012; 83: 299\u2013365.","DOI":"10.1016\/B978-0-12-394438-2.00007-4"},{"key":"ref50","doi-asserted-by":"publisher","unstructured":"Pastagia M, Schuch R, Fischetti VA, Huang DB. Lysins: the arrival of pathogen-directed anti-infectives. Journal of Medical Microbiology. 2013; 62: 1506\u20131516.","DOI":"10.1099\/jmm.0.061028-0"},{"key":"ref51","doi-asserted-by":"publisher","unstructured":"Broendum SS, Buckle AM, McGowan S. Catalytic diversity and cell wall binding repeats in the phage-encoded endolysins. Molecular Microbiology. 2018; 110: 879\u2013896.","DOI":"10.1111\/mmi.14134"},{"key":"ref52","doi-asserted-by":"publisher","unstructured":"Love MJ, Abeysekera GS, Muscroft-Taylor AC, Billington C, Dobson RCJ. On the catalytic mechanism of bacteriophage endolysins: Opportunities for engineering. Biochimica et Biophysica Acta. Proteins and Proteomics. 2020; 1868: 140302.","DOI":"10.1016\/j.bbapap.2019.140302"},{"key":"ref53","doi-asserted-by":"publisher","unstructured":"Wong KY, Megat Mazhar Khair MH, Song AAL, Masarudin MJ, Chong CM, In LLA, et al. Endolysins against Streptococci as an antibiotic alternative. Frontiers in Microbiology. 2022; 13: 935145.","DOI":"10.3389\/fmicb.2022.935145"},{"key":"ref54","doi-asserted-by":"publisher","unstructured":"Briers Y, Volckaert G, Cornelissen A, Lagaert S, Michiels CW, Hertveldt K, et al. Muralytic activity and modular structure of the endolysins of Pseudomonas aeruginosa bacteriophages phiKZ and EL. Molecular Microbiology. 2007; 65: 1334\u20131344.","DOI":"10.1111\/j.1365-2958.2007.05870.x"},{"key":"ref55","doi-asserted-by":"publisher","unstructured":"Borysowski J, Weber-Dabrowska B, G\u00f3rski A. Bacteriophage endolysins as a novel class of antibacterial agents. Experimental Biology and Medicine (Maywood, N.J.). 2006; 231: 366\u2013377.","DOI":"10.1177\/153537020623100402"},{"key":"ref56","doi-asserted-by":"publisher","unstructured":"Vidov\u00e1 B, \u0160ramkov\u00e1 Z, Ti\u0161\u00e1kov\u00e1 L, Oravkinov\u00e1 M, God\u00e1ny A. Bioinformatics analysis of bacteriophage and prophage endolysin domains. Biologia. 2014; 69: 541\u2013556.","DOI":"10.2478\/s11756-014-0358-8"},{"key":"ref57","doi-asserted-by":"publisher","unstructured":"Pohane AA, Joshi H, Jain V. Molecular dissection of phage endolysin: an interdomain interaction confers host specificity in lysin A of Mycobacterium phage D29. The Journal of Biological Chemistry. 2014; 289: 12085\u201312095.","DOI":"10.1074\/jbc.M113.529594"},{"key":"ref58","doi-asserted-by":"publisher","unstructured":"Briers Y. Phage lytic enzymes. Viruses. 2019; 11: 113.","DOI":"10.3390\/v11020113"},{"key":"ref59","doi-asserted-by":"publisher","unstructured":"Alcorlo M, Mart\u00ednez-Caballero S, Molina R, Hermoso JA. Carbohydrate recognition and lysis by bacterial peptidoglycan hydrolases. Current Opinion in Structural Biology. 2017; 44: 87\u2013100.","DOI":"10.1016\/j.sbi.2017.01.001"},{"key":"ref60","doi-asserted-by":"publisher","unstructured":"Schmelcher M, Donovan DM, Loessner MJ. Bacteriophage endolysins as novel antimicrobials. Future Microbiology. 2012; 7: 1147\u20131171.","DOI":"10.2217\/fmb.12.97"},{"key":"ref61","doi-asserted-by":"publisher","unstructured":"Yang Z, Du X, Hu N, Feng M, Xu J, Jiang H, et al. A novel enterococcus phage endolysin Lys22 with a wide host range against mixed biofilm of Enterococcus faecalis, Staphylococcus aureus and Acinetobacter baumannii. bioRxiv. 2025.  (preprint)","DOI":"10.1101\/2025.03.11.642608"},{"key":"ref62","doi-asserted-by":"publisher","unstructured":"Grabowski \u0141, \u0141epek K, Stasi\u0142oj\u0107 M, Kosznik-Kwa\u015bnicka K, Zdrojewska K, Maci\u0105g-Dorszy\u0144ska M, et al. Bacteriophage-encoded enzymes destroying bacterial cell membranes and walls, and their potential use as antimicrobial agents. Microbiological Research. 2021; 248: 126746.","DOI":"10.1016\/j.micres.2021.126746"},{"key":"ref63","doi-asserted-by":"publisher","unstructured":"Wang IN, Smith DL, Young R. Holins: the protein clocks of bacteriophage infections. Annual Review of Microbiology. 2000; 54: 799\u2013825.","DOI":"10.1146\/annurev.micro.54.1.799"},{"key":"ref64","doi-asserted-by":"publisher","unstructured":"Vollmer W, Blanot D, de Pedro MA. Peptidoglycan structure and architecture. FEMS Microbiology Reviews. 2008; 32: 149\u2013167.","DOI":"10.1111\/j.1574-6976.2007.00094.x"},{"key":"ref65","doi-asserted-by":"publisher","unstructured":"Maciejewska B, \u0179rubek K, Espaillat A, Wi\u015bniewska M, Rembacz KP, Cava F, et al. Modular endolysin of Burkholderia AP3 phage has the largest lysozyme-like catalytic subunit discovered to date and no catalytic aspartate residue. Scientific Reports. 2017; 7: 14501.","DOI":"10.1038\/s41598-017-14797-9"},{"key":"ref66","doi-asserted-by":"publisher","unstructured":"Maciejewska B, Olszak T, Drulis-Kawa Z. Applications of bacteriophages versus phage enzymes to combat and cure bacterial infections: an ambitious and also a realistic application? Applied Microbiology and Biotechnology. 2018; 102: 2563\u20132581.","DOI":"10.1007\/s00253-018-8811-1"},{"key":"ref67","doi-asserted-by":"publisher","unstructured":"Bai J, Lee S, Ryu S. Identification and in vitro characterization of a novel phage endolysin that targets Gram-negative bacteria. Microorganisms. 2020; 8: 447.","DOI":"10.3390\/microorganisms8030447"},{"key":"ref68","doi-asserted-by":"publisher","unstructured":"Kim S, Jin JS, Choi YJ, Kim J. LysSAP26, a new recombinant phage endolysin with a broad spectrum antibacterial activity. Viruses. 2020; 12: 1340.","DOI":"10.3390\/v12111340"},{"key":"ref69","doi-asserted-by":"publisher","unstructured":"Wertheim HFL, Melles DC, Vos MC, van Leeuwen W, van Belkum A, Verbrugh HA, et al. The role of nasal carriage in Staphylococcus aureus infections. The Lancet. Infectious Diseases. 2005; 5: 751\u2013762.","DOI":"10.1016\/S1473-3099(05)70295-4"},{"key":"ref70","doi-asserted-by":"publisher","unstructured":"Fowler VG, Jr, Das AF, Lipka-Diamond J, Schuch R, Pomerantz R, J\u00e1uregui-Peredo L, et al. Exebacase for patients with Staphylococcus aureus bloodstream infection and endocarditis. The Journal of Clinical Investigation. 2020; 130: 3750\u20133760.","DOI":"10.1172\/JCI136577"},{"key":"ref71","doi-asserted-by":"publisher","unstructured":"Vipra AA, Desai SN, Roy P, Patil R, Raj JM, Narasimhaswamy N, et al. Antistaphylococcal activity of bacteriophage derived chimeric protein P128. BMC Microbiology. 2012; 12: 41.","DOI":"10.1186\/1471-2180-12-41"},{"key":"ref72","doi-asserted-by":"publisher","unstructured":"Schleimer N, Kaspar U, Knaack D, von Eiff C, Molinaro S, Grallert H, et al. In vitro activity of the bacteriophage endolysin HY-133 against Staphylococcus aureus small-colony variants and their corresponding wild types. International Journal of Molecular Sciences. 2019; 20: 716.","DOI":"10.3390\/ijms20030716"},{"key":"ref73","doi-asserted-by":"publisher","unstructured":"Idelevich EA, Schaumburg F, Knaack D, Scherzinger AS, Mutter W, Peters G, et al. The Recombinant bacteriophage endolysin HY-133 exhibits in vitro activity against different african clonal lineages of the Staphylococcus aureus complex, including Staphylococcus schweitzeri. Antimicrobial Agents and Chemotherapy. 2016; 60: 2551\u20132553.","DOI":"10.1128\/AAC.02859-15"},{"key":"ref74","doi-asserted-by":"publisher","unstructured":"Kaspar U, de Haro Sautto JA, Molinaro S, Peters G, Idelevich EA, Becker K. The novel phage-derived antimicrobial agent HY-133 is active against livestock-associated methicillin-resistant Staphylococcus aureus. Antimicrobial Agents and Chemotherapy. 2018; 62: e00385\u201318.","DOI":"10.1128\/AAC.00385-18"},{"key":"ref75","doi-asserted-by":"publisher","unstructured":"Knaack D, Idelevich EA, Schleimer N, Molinaro S, Kriegeskorte A, Peters G, et al. Bactericidal activity of bacteriophage endolysin HY-133 against Staphylococcus aureus in comparison to other antibiotics as determined by minimum bactericidal concentrations and time-kill analysis. Diagnostic Microbiology and Infectious Disease. 2019; 93: 362\u2013368.","DOI":"10.1016\/j.diagmicrobio.2018.11.005"},{"key":"ref76","doi-asserted-by":"publisher","unstructured":"Schmelcher M, Shen Y, Nelson DC, Eugster MR, Eichenseher F, Hanke DC, et al. Evolutionarily distinct bacteriophage endolysins featuring conserved peptidoglycan cleavage sites protect mice from MRSA infection. The Journal of Antimicrobial Chemotherapy. 2015; 70: 1453\u20131465.","DOI":"10.1093\/jac\/dku552"},{"key":"ref77","doi-asserted-by":"publisher","unstructured":"Idelevich EA, von Eiff C, Friedrich AW, Iannelli D, Xia G, Peters G, et al. In vitro activity against Staphylococcus aureus of a novel antimicrobial agent, PRF-119, a recombinant chimeric bacteriophage endolysin. Antimicrobial Agents and Chemotherapy. 2011; 55: 4416\u20134419.","DOI":"10.1128\/AAC.00217-11"},{"key":"ref78","doi-asserted-by":"publisher","unstructured":"Liu H, Wei X, Wang Z, Huang X, Li M, Hu Z, et al. LysSYL: a broad-spectrum phage endolysin targeting Staphylococcus species and eradicating S. aureus biofilms. Microbial Cell Factories. 2024; 23: 89.","DOI":"10.1186\/s12934-024-02359-4"},{"key":"ref79","doi-asserted-by":"publisher","unstructured":"Chang Y, Kim M, Ryu S. Characterization of a novel endolysin LysSA11 and its utility as a potent biocontrol agent against Staphylococcus aureus on food and utensils. Food Microbiology. 2017; 68: 112\u2013120.","DOI":"10.1016\/j.fm.2017.07.004"},{"key":"ref80","doi-asserted-by":"publisher","unstructured":"Zhang L, Li D, Li X, Hu L, Cheng M, Xia F, et al. LysGH15 kills Staphylococcus aureus without being affected by the humoral immune response or inducing inflammation. Scientific Reports. 2016; 6: 29344.","DOI":"10.1038\/srep29344"},{"key":"ref81","doi-asserted-by":"publisher","unstructured":"Ning H, Lin H, Wang J, He X, Lv X, Ju L. Characterizations of the endolysin Lys84 and its domains from phage qdsa002 with high activities against Staphylococcus aureus and its biofilms. Enzyme and Microbial Technology. 2021; 148: 109809.","DOI":"10.1016\/j.enzmictec.2021.109809"},{"key":"ref82","doi-asserted-by":"publisher","unstructured":"Kuiper JWP, Hogervorst JMA, Herpers BL, Bakker AD, Klein-Nulend J, Nolte PA, et al. The novel endolysin XZ.700 effectively treats MRSA biofilms in two biofilm models without showing toxicity on human bone cells in vitro. Biofouling. 2021; 37: 184\u2013193.","DOI":"10.1080\/08927014.2021.1887151"},{"key":"ref83","doi-asserted-by":"publisher","unstructured":"Son B, Kong M, Ryu S. The auxiliary role of the amidase domain in cell wall binding and exolytic activity of Staphylococcal phage endolysins. Viruses. 2018; 10: 284.","DOI":"10.3390\/v10060284"},{"key":"ref84","doi-asserted-by":"publisher","unstructured":"Rashel M, Uchiyama J, Ujihara T, Uehara Y, Kuramoto S, Sugihara S, et al. Efficient elimination of multidrug-resistant Staphylococcus aureus by cloned lysin derived from bacteriophage phi MR11. The Journal of Infectious Diseases. 2007; 196: 1237\u20131247.","DOI":"10.1086\/521305"},{"key":"ref85","doi-asserted-by":"publisher","unstructured":"Son JS, Lee SJ, Jun SY, Yoon SJ, Kang SH, Paik HR, et al. Antibacterial and biofilm removal activity of a podoviridae Staphylococcus aureus bacteriophage SAP-2 and a derived recombinant cell-wall-degrading enzyme. Applied Microbiology and Biotechnology. 2010; 86: 1439\u20131449.","DOI":"10.1007\/s00253-009-2386-9"},{"key":"ref86","doi-asserted-by":"publisher","unstructured":"Meng X, Shi Y, Ji W, Meng X, Zhang J, Wang H, et al. Application of a bacteriophage lysin to disrupt biofilms formed by the animal pathogen Streptococcus suis. Applied and Environmental Microbiology. 2011; 77: 8272\u20138279.","DOI":"10.1128\/AEM.05151-11"},{"key":"ref87","doi-asserted-by":"publisher","unstructured":"Wang Y, Sun JH, Lu CP. Purified recombinant phage lysin LySMP: an extensive spectrum of lytic activity for swine streptococci. Current Microbiology. 2009; 58: 609\u2013615.","DOI":"10.1007\/s00284-009-9379-x"},{"key":"ref88","doi-asserted-by":"publisher","unstructured":"Poonacha N, Nair S, Desai S, Tuppad D, Hiremath D, Mohan T, et al. Efficient killing of planktonic and biofilm-embedded coagulase-negative Staphylococci by bactericidal protein P128. Antimicrobial Agents and Chemotherapy. 2017; 61: e00457\u201317.","DOI":"10.1128\/AAC.00457-17"},{"key":"ref89","doi-asserted-by":"publisher","unstructured":"Indiani C, Sauve K, Raz A, Abdelhady W, Xiong YQ, Cassino C, et al. The antistaphylococcal lysin, CF-301, activates key host factors in human blood to potentiate methicillin-resistant Staphylococcus aureus bacteriolysis. Antimicrobial Agents and Chemotherapy. 2019; 63: e02291\u201318.","DOI":"10.1128\/AAC.02291-18"},{"key":"ref90","doi-asserted-by":"publisher","unstructured":"Wang J, Liang S, Lu X, Xu Q, Zhu Y, Yu S, et al. Bacteriophage endolysin Ply113 as a potent antibacterial agent against polymicrobial biofilms formed by enterococci and Staphylococcus aureus. Frontiers in Microbiology. 2023; 14: 1304932.","DOI":"10.3389\/fmicb.2023.1304932"},{"key":"ref91","doi-asserted-by":"publisher","unstructured":"Li W, Yang H, Gong Y, Wang S, Li Y, Wei H. Effects of a chimeric lysin against planktonic and sessile Enterococcus faecalis hint at potential application in endodontic therapy. Viruses. 2018; 10: 290.","DOI":"10.3390\/v10060290"},{"key":"ref92","doi-asserted-by":"publisher","unstructured":"Yang D, Chen Y, Sun E, Hua L, Peng Z, Wu B. Characterization of a lytic bacteriophage vB_EfaS_PHB08 harboring endolysin Lys08 against Enterococcus faecalis biofilms. Microorganisms. 2020; 8: 1332.","DOI":"10.3390\/microorganisms8091332"},{"key":"ref93","doi-asserted-by":"publisher","unstructured":"Cheng M, Zhang Y, Li X, Liang J, Hu L, Gong P, et al. Endolysin LysEF-P10 shows potential as an alternative treatment strategy for multidrug-resistant Enterococcus faecalis infections. Scientific Reports. 2017; 7: 10164.","DOI":"10.1038\/s41598-017-10755-7"},{"key":"ref94","doi-asserted-by":"publisher","unstructured":"Zhou B, Zhen X, Zhou H, Zhao F, Fan C, Per\u010dulija V, et al. Structural and functional insights into a novel two-component endolysin encoded by a single gene in Enterococcus faecalis phage. PLoS Pathogens. 2020; 16: e1008394.","DOI":"10.1371\/journal.ppat.1008394"},{"key":"ref95","doi-asserted-by":"publisher","unstructured":"Entenza JM, Loeffler JM, Grandgirard D, Fischetti VA, Moreillon P. Therapeutic effects of bacteriophage Cpl-1 lysin against Streptococcus pneumoniae endocarditis in rats. Antimicrobial Agents and Chemotherapy. 2005; 49: 4789\u20134792.","DOI":"10.1128\/AAC.49.11.4789-4792.2005"},{"key":"ref96","doi-asserted-by":"publisher","unstructured":"Doehn JM, Fischer K, Reppe K, Gutbier B, Tschernig T, Hocke AC, et al. Delivery of the endolysin Cpl-1 by inhalation rescues mice with fatal pneumococcal pneumonia. The Journal of Antimicrobial Chemotherapy. 2013; 68: 2111\u20132117.","DOI":"10.1093\/jac\/dkt131"},{"key":"ref97","doi-asserted-by":"publisher","unstructured":"Bustamante N, Campillo NE, Garc\u00eda E, Gallego C, Pera B, Diakun GP, et al. Cpl-7, a lysozyme encoded by a pneumococcal bacteriophage with a novel cell wall-binding motif. The Journal of Biological Chemistry. 2010; 285: 33184\u201333196.","DOI":"10.1074\/jbc.M110.154559"},{"key":"ref98","doi-asserted-by":"publisher","unstructured":"D\u00edez-Mart\u00ednez R, de Paz HD, Bustamante N, Garc\u00eda E, Men\u00e9ndez M, Garc\u00eda P. Improving the lethal effect of cpl-7, a pneumococcal phage lysozyme with broad bactericidal activity, by inverting the net charge of its cell wall-binding module. Antimicrobial Agents and Chemotherapy. 2013; 57: 5355\u20135365.","DOI":"10.1128\/AAC.01372-13"},{"key":"ref99","doi-asserted-by":"publisher","unstructured":"Xu J, Yang H, Bi Y, Li W, Wei H, Li Y. Activity of the Chimeric Lysin ClyR against Common Gram-Positive Oral Microbes and Its Anticaries Efficacy in Rat Models. Viruses. 2018; 10: 380.","DOI":"10.3390\/v10070380"},{"key":"ref100","doi-asserted-by":"publisher","unstructured":"Alreja AB, Appel AE, Zhu JC, Riley SP, Gonzalez-Juarbe N, Nelson DC. SP-CHAP, an endolysin with enhanced activity against biofilm pneumococci and nasopharyngeal colonization. mBio. 2024; 15: e0006924.","DOI":"10.1128\/mbio.00069-24"},{"key":"ref101","doi-asserted-by":"publisher","unstructured":"Vander Elst N, Linden SB, Lavigne R, Meyer E, Briers Y, Nelson DC. Characterization of the bacteriophage-derived endolysins PlySs2 and PlySs9 with in vitro lytic activity against bovine mastitis Streptococcus uberis. Antibiotics (Basel, Switzerland). 2020; 9: 621.","DOI":"10.3390\/antibiotics9090621"},{"key":"ref102","doi-asserted-by":"publisher","unstructured":"Kim H, Lee HG, Kwon I, Seo J. Characterization of endolysin LyJH307 with antimicrobial activity against Streptococcus bovis. Animals. 2020; 10: 963.","DOI":"10.3390\/ani10060963"},{"key":"ref103","doi-asserted-by":"publisher","unstructured":"Nelson D, Loomis L, Fischetti VA. Prevention and elimination of upper respiratory colonization of mice by group A streptococci by using a bacteriophage lytic enzyme. Proceedings of the National Academy of Sciences of the United States of America. 2001; 98: 4107\u20134112.","DOI":"10.1073\/pnas.061038398"},{"key":"ref104","doi-asserted-by":"publisher","unstructured":"Lood R, Raz A, Molina H, Euler CW, Fischetti VA. A highly active and negatively charged Streptococcus pyogenes lysin with a rare D-alanyl-L-alanine endopeptidase activity protects mice against streptococcal bacteremia. Antimicrobial Agents and Chemotherapy. 2014; 58: 3073\u20133084.","DOI":"10.1128\/AAC.00115-14"},{"key":"ref105","doi-asserted-by":"publisher","unstructured":"Shen Y, K\u00f6ller T, Kreikemeyer B, Nelson DC. Rapid degradation of Streptococcus pyogenes biofilms by PlyC, a bacteriophage-encoded endolysin. The Journal of Antimicrobial Chemotherapy. 2013; 68: 1818\u20131824.","DOI":"10.1093\/jac\/dkt104"},{"key":"ref106","doi-asserted-by":"publisher","unstructured":"Huang L, Luo D, Gondil VS, Gong Y, Jia M, Yan D, et al. Construction and characterization of a chimeric lysin ClyV with improved bactericidal activity against Streptococcus agalactiae in vitro and in vivo. Applied Microbiology and Biotechnology. 2020; 104: 1609\u20131619.","DOI":"10.1007\/s00253-019-10325-z"},{"key":"ref107","doi-asserted-by":"publisher","unstructured":"Cheng Q, Nelson D, Zhu S, Fischetti VA. Removal of group B streptococci colonizing the vagina and oropharynx of mice with a bacteriophage lytic enzyme. Antimicrobial Agents and Chemotherapy. 2005; 49: 111\u2013117.","DOI":"10.1128\/AAC.49.1.111-117.2005"},{"key":"ref108","doi-asserted-by":"publisher","unstructured":"Oechslin F, Daraspe J, Giddey M, Moreillon P, Resch G. In vitro characterization of PlySK1249, a novel phage lysin, and assessment of its antibacterial activity in a mouse model of Streptococcus agalactiae bacteremia. Antimicrobial Agents and Chemotherapy. 2013; 57: 6276\u20136283.","DOI":"10.1128\/AAC.01701-13"},{"key":"ref109","doi-asserted-by":"publisher","unstructured":"Wang Z, Ma J, Wang J, Yang D, Kong L, Fu Q, et al. Application of the phage lysin Ply5218 in the treatment of Streptococcus suis infection in piglets. Viruses. 2019; 11: 715.","DOI":"10.3390\/v11080715"},{"key":"ref110","doi-asserted-by":"publisher","unstructured":"Lu R, Liu B, Wu L, Bao H, Garc\u00eda P, Wang Y, et al. A Broad-spectrum phage endolysin (LysCP28) able to remove biofilms and inactivate Clostridium perfringens strains. Foods (Basel, Switzerland). 2023; 12: 411.","DOI":"10.3390\/foods12020411"},{"key":"ref111","doi-asserted-by":"publisher","unstructured":"Schuch R, Nelson D, Fischetti VA. A bacteriolytic agent that detects and kills Bacillus anthracis. Nature. 2002; 418: 884\u2013889.","DOI":"10.1038\/nature01026"},{"key":"ref112","doi-asserted-by":"publisher","unstructured":"Park S, Jun SY, Kim CH, Jung GM, Son JS, Jeong ST, et al. Characterisation of the antibacterial properties of the recombinant phage endolysins AP50-31 and LysB4 as potent bactericidal agents against Bacillus anthracis. Scientific Reports. 2018; 8: 18.","DOI":"10.1038\/s41598-017-18535-z"},{"key":"ref113","doi-asserted-by":"publisher","unstructured":"Schuch R, Pelzek AJ, Nelson DC, Fischetti VA. The PlyB endolysin of bacteriophage vB_BanS_Bcp1 exhibits broad-spectrum bactericidal activity against Bacillus cereus Sensu Lato Isolates. Applied and Environmental Microbiology. 2019; 85: e00003-19.","DOI":"10.1128\/AEM.00003-19"},{"key":"ref114","doi-asserted-by":"publisher","unstructured":"\u017bebrowska J, \u017bo\u0142nierkiewicz O, Ponikowska M, Puchalski M, Krawczun N, Makowska J, et al. Cloning and characterization of a thermostable endolysin of bacteriophage TP-84 as a potential disinfectant and biofilm-removing biological agent. International Journal of Molecular Sciences. 2022; 23: 7612.","DOI":"10.3390\/ijms23147612"},{"key":"ref115","doi-asserted-by":"publisher","unstructured":"Briers Y, Walmagh M, Van Puyenbroeck V, Cornelissen A, Cenens W, Aertsen A, et al. Engineered endolysin-based \u201cArtilysins\u201d to combat multidrug-resistant gram-negative pathogens. mBio. 2014; 5: e01379-14.","DOI":"10.1128\/mBio.01379-14"},{"key":"ref116","doi-asserted-by":"publisher","unstructured":"Raz A, Serrano A, Hernandez A, Euler CW, Fischetti VA. Isolation of phage lysins that effectively kill Pseudomonas aeruginosa in mouse models of lung and skin infection. Antimicrobial Agents and Chemotherapy. 2019; 63: e00024-19.","DOI":"10.1128\/AAC.00024-19"},{"key":"ref117","doi-asserted-by":"publisher","unstructured":"Fursov MV, Abdrakhmanova RO, Antonova NP, Vasina DV, Kolchanova AD, Bashkina OA, et al. Antibiofilm activity of a broad-range recombinant endolysin LysECD7: In vitro and in vivo study. Viruses. 2020; 12: 545.","DOI":"10.3390\/v12050545"},{"key":"ref118","doi-asserted-by":"publisher","unstructured":"Vasina DV, Antonova NP, Grigoriev IV, Yakimakha VS, Lendel AM, Nikiforova MA, et al. Discovering the potentials of four phage endolysins to combat Gram-negative infections. Frontiers in Microbiology. 2021; 12: 748718.","DOI":"10.3389\/fmicb.2021.748718"},{"key":"ref119","doi-asserted-by":"publisher","unstructured":"Soontarach R, Srimanote P, Voravuthikunchai SP, Chusri S. Antibacterial and anti-biofilm efficacy of endolysin LysAB1245 against a panel of important pathogens. Pharmaceuticals (Basel, Switzerland). 2024; 17: 155.","DOI":"10.3390\/ph17020155"},{"key":"ref120","doi-asserted-by":"publisher","unstructured":"Lood R, Winer BY, Pelzek AJ, Diez-Martinez R, Thandar M, Euler CW, et al. Novel phage lysin capable of killing the multidrug-resistant gram-negative bacterium Acinetobacter baumannii in a mouse bacteremia model. Antimicrobial Agents and Chemotherapy. 2015; 59: 1983\u20131991.","DOI":"10.1128\/AAC.04641-14"},{"key":"ref121","doi-asserted-by":"publisher","unstructured":"Kim S, Lee DW, Jin JS, Kim J. Antimicrobial activity of LysSS, a novel phage endolysin, against Acinetobacter baumannii and Pseudomonas aeruginosa. Journal of Global Antimicrobial Resistance. 2020; 22: 32\u201339.","DOI":"10.1016\/j.jgar.2020.01.005"},{"key":"ref122","doi-asserted-by":"publisher","unstructured":"Yan G, Yang R, Fan K, Dong H, Gao C, Wang S, et al. External lysis of Escherichia coli by a bacteriophage endolysin modified with hydrophobic amino acids. AMB Express. 2019; 9: 106.","DOI":"10.1186\/s13568-019-0838-x"},{"key":"ref123","doi-asserted-by":"publisher","unstructured":"Larpin Y, Oechslin F, Moreillon P, Resch G, Entenza JM, Mancini S. In vitro characterization of PlyE146, a novel phage lysin that targets Gram-negative bacteria. PloS One. 2018; 13: e0192507.","DOI":"10.1371\/journal.pone.0192507"},{"key":"ref124","doi-asserted-by":"publisher","unstructured":"Arroyo-Moreno S, Cummings M, Corcoran DB, Coffey A, McCarthy RR. Identification and characterization of novel endolysins targeting Gardnerella vaginalis biofilms to treat bacterial vaginosis. NPJ Biofilms and Microbiomes. 2022; 8: 29.","DOI":"10.1038\/s41522-022-00285-0"},{"key":"ref125","doi-asserted-by":"publisher","unstructured":"Landlinger C, Oberbauer V, Podpera Tisakova L, Schwebs T, Berdaguer R, Van Simaey L, et al. Preclinical data on the Gardnerella-specific endolysin PM-477 indicate its potential to improve the treatment of bacterial vaginosis through enhanced biofilm removal and avoidance of resistance. Antimicrobial Agents and Chemotherapy. 2022; 66: e0231921.","DOI":"10.1128\/aac.02319-21"},{"key":"ref126","doi-asserted-by":"publisher","unstructured":"Johnston W, Ware A, Kuiters WF, Delaney C, Brown JL, Hagen S, et al. In vitro bacterial vaginosis biofilm community manipulation using endolysin therapy. Biofilm. 2022; 5: 100101.","DOI":"10.1016\/j.bioflm.2022.100101"},{"key":"ref127","doi-asserted-by":"publisher","unstructured":"Eghbalpoor F, Gorji M, Alavigeh MZ, Moghadam MT. Genetically engineered phages and engineered phage-derived enzymes to destroy biofilms of antibiotics resistance bacteria. Heliyon. 2024; 10: e35666.","DOI":"10.1016\/j.heliyon.2024.e35666"},{"key":"ref128","doi-asserted-by":"publisher","unstructured":"Linden SB, Zhang H, Heselpoth RD, Shen Y, Schmelcher M, Eichenseher F, et al. Biochemical and biophysical characterization of PlyGRCS, a bacteriophage endolysin active against methicillin-resistant Staphylococcus aureus. Applied Microbiology and Biotechnology. 2015; 99: 741\u2013752.","DOI":"10.1007\/s00253-014-5930-1"},{"key":"ref129","doi-asserted-by":"publisher","unstructured":"Golban M, Charostad J, Kazemian H, Heidari H. Phage-derived endolysins against resistant Staphylococcus spp.: A review of features, antibacterial activities, and recent applications. Infectious Diseases and Therapy. 2025; 14: 13\u201357.","DOI":"10.1007\/s40121-024-01069-z"},{"key":"ref130","doi-asserted-by":"publisher","unstructured":"Cattoir V. The multifaceted lifestyle of enterococci: genetic diversity, ecology and risks for public health. Current Opinion in Microbiology. 2022; 65: 73\u201380.","DOI":"10.1016\/j.mib.2021.10.013"},{"key":"ref131","doi-asserted-by":"publisher","unstructured":"Byappanahalli MN, Nevers MB, Korajkic A, Staley ZR, Harwood VJ. Enterococci in the environment. Microbiology and Molecular Biology Reviews: MMBR. 2012; 76: 685\u2013706.","DOI":"10.1128\/MMBR.00023-12"},{"key":"ref132","doi-asserted-by":"publisher","unstructured":"Guzman Prieto AM, van Schaik W, Rogers MRC, Coque TM, Baquero F, Corander J, et al. Global emergence and dissemination of Enterococci as nosocomial pathogens: Attack of the clones? Frontiers in Microbiology. 2016; 7: 788.","DOI":"10.3389\/fmicb.2016.00788"},{"key":"ref133","doi-asserted-by":"publisher","unstructured":"Ayobami O, Willrich N, Reuss A, Eckmanns T, Markwart R. The ongoing challenge of vancomycin-resistant Enterococcus faecium and Enterococcus faecalis in Europe: an epidemiological analysis of bloodstream infections. Emerging Microbes & Infections. 2020; 9: 1180\u20131193.","DOI":"10.1080\/22221751.2020.1769500"},{"key":"ref134","doi-asserted-by":"publisher","unstructured":"Church D, Elsayed S, Reid O, Winston B, Lindsay R. Burn wound infections. Clinical Microbiology Reviews. 2006; 19: 403\u2013434.","DOI":"10.1128\/CMR.19.2.403-434.2006"},{"key":"ref135","doi-asserted-by":"publisher","unstructured":"Guerra MES, Destro G, Vieira B, Lima AS, Ferraz LFC, Hakansson AP, et al. Klebsiella pneumoniae biofilms and their role in disease pathogenesis. Frontiers in Cellular and Infection Microbiology. 2022; 12: 877995.","DOI":"10.3389\/fcimb.2022.877995"},{"key":"ref136","doi-asserted-by":"publisher","unstructured":"Khan FM, Rasheed F, Yang Y, Liu B, Zhang R. Endolysins: a new antimicrobial agent against antimicrobial resistance. Strategies and opportunities in overcoming the challenges of endolysins against Gram-negative bacteria. Frontiers in Pharmacology. 2024; 15: 1385261.","DOI":"10.3389\/fphar.2024.1385261"},{"key":"ref137","doi-asserted-by":"publisher","unstructured":"Sadhu K, Domingue PA, Chow AW, Nelligan J, Cheng N, Costerton JW. Gardnerella vaginalis has a Gram-positive cell-wall ultrastructure and lacks classical cell-wall lipopolysaccharide. Journal of Medical Microbiology. 1989; 29: 229\u2013235.","DOI":"10.1099\/00222615-29-3-229"},{"key":"ref138","doi-asserted-by":"publisher","unstructured":"Vaneechoutte M, Guschin A, Van Simaey L, Gansemans Y, Van Nieuwerburgh F, Cools P. Emended description of Gardnerella vaginalis and description of Gardnerella leopoldii sp. nov., Gardnerella piotii sp. nov. and Gardnerella swidsinskii sp. nov., with delineation of 13 genomic species within the genus Gardnerella. International Journal of Systematic and Evolutionary Microbiology. 2019; 69: 679\u2013687.","DOI":"10.1099\/ijsem.0.003200"},{"key":"ref139","doi-asserted-by":"publisher","unstructured":"Rodr\u00edguez-Cerrato V, Garc\u00eda P, Del Prado G, Garc\u00eda E, Gracia M, Huelves L, et al. In vitro interactions of LytA, the major pneumococcal autolysin, with two bacteriophage lytic enzymes (Cpl-1 and Pal), cefotaxime and moxifloxacin against antibiotic-susceptible and -resistant Streptococcus pneumoniae strains. The Journal of Antimicrobial Chemotherapy. 2007; 60: 1159\u20131162.","DOI":"10.1093\/jac\/dkm342"},{"key":"ref140","doi-asserted-by":"publisher","unstructured":"Djurkovic S, Loeffler JM, Fischetti VA. Synergistic killing of Streptococcus pneumoniae with the bacteriophage lytic enzyme Cpl-1 and penicillin or gentamicin depends on the level of penicillin resistance. Antimicrobial Agents and Chemotherapy. 2005; 49: 1225\u20131228.","DOI":"10.1128\/AAC.49.3.1225-1228.2005"},{"key":"ref141","doi-asserted-by":"publisher","unstructured":"Kim NH, Park WB, Cho JE, Choi YJ, Choi SJ, Jun SY, et al. Effects of phage endolysin SAL200 combined with antibiotics on Staphylococcus aureus infection. Antimicrobial Agents and Chemotherapy. 2018; 62: e00731\u201318.","DOI":"10.1128\/AAC.00731-18"},{"key":"ref142","doi-asserted-by":"publisher","unstructured":"Oh HK, Hwang YJ, Hong HW, Myung H. Comparison of Enterococcus faecalis biofilm removal efficiency among bacteriophage PBEF129, its endolysin, and cefotaxime. Viruses. 2021; 13: 426.","DOI":"10.3390\/v13030426"},{"key":"ref143","doi-asserted-by":"publisher","unstructured":"Lu H, Li Z, Elbaz A, Ni SQ. Synergistic action of phages and lytic proteins with antibiotics: a combination strategy to target bacteria and biofilms. BMC Microbiology. 2023; 23: 149.","DOI":"10.1186\/s12866-023-02881-2"},{"key":"ref144","doi-asserted-by":"publisher","unstructured":"Singh PK, Donovan DM, Kumar A. Intravitreal injection of the chimeric phage endolysin Ply187 protects mice from Staphylococcus aureus endophthalmitis. Antimicrobial Agents and Chemotherapy. 2014; 58: 4621\u20134629.","DOI":"10.1128\/AAC.00126-14"},{"key":"ref145","doi-asserted-by":"publisher","unstructured":"Zhang J, Xu LL, Gan D, Zhang X. In vitro study of bacteriophage AB3 endolysin LysAB3 activity against Acinetobacter baumannii biofilm and biofilm-bound A. baumannii. Clinical Laboratory. 2018; 64: 1021\u20131030.","DOI":"10.7754\/Clin.Lab.2018.180342"},{"key":"ref146","doi-asserted-by":"publisher","unstructured":"Donovan DM, Dong S, Garrett W, Rousseau GM, Moineau S, Pritchard DG. Peptidoglycan hydrolase fusions maintain their parental specificities. Applied and Environmental Microbiology. 2006; 72: 2988\u20132996.","DOI":"10.1128\/AEM.72.4.2988-2996.2006"},{"key":"ref147","doi-asserted-by":"publisher","unstructured":"Zhang H, Zhang X, Liang S, Wang J, Zhu Y, Zhang W, et al. Bactericidal synergism between phage endolysin Ply2660 and cathelicidin LL-37 against vancomycin-resistant Enterococcus faecalis biofilms. NPJ Biofilms and Microbiomes. 2023; 9: 16.","DOI":"10.1038\/s41522-023-00385-5"},{"key":"ref148","doi-asserted-by":"publisher","unstructured":"Islam MM, Kim D, Kim K, Park SJ, Akter S, Kim J, et al. Engineering of lysin by fusion of antimicrobial peptide (cecropin A) enhances its antibacterial properties against multidrug-resistant Acinetobacter baumannii. Frontiers in Microbiology. 2022; 13: 988522.","DOI":"10.3389\/fmicb.2022.988522"},{"key":"ref149","doi-asserted-by":"publisher","unstructured":"Baliga P, Goolappa PT, Shekar M, Kallappa GS. Cloning, Characterization, and Antibacterial Properties of Endolysin LysE Against Planktonic Cells and Biofilms of Aeromonas hydrophila. Probiotics and Antimicrobial Proteins. 2023; 15: 646\u2013654.","DOI":"10.1007\/s12602-021-09880-7"},{"key":"ref150","doi-asserted-by":"publisher","unstructured":"Oliveira H, Thiagarajan V, Walmagh M, Sillankorva S, Lavigne R, Neves-Petersen MT, et al. A thermostable Salmonella phage endolysin, Lys68, with broad bactericidal properties against gram-negative pathogens in presence of weak acids. PloS One. 2014; 9: e108376.","DOI":"10.1371\/journal.pone.0108376"},{"key":"ref151","doi-asserted-by":"publisher","unstructured":"Filatova LY, Donovan DM, Ishnazarova NT, Foster-Frey JA, Becker SC, Pugachev VG, et al. A chimeric LysK-lysostaphin fusion enzyme lysing Staphylococcus aureus cells: A study of both kinetics of inactivation and specifics of interaction with anionic polymers. Applied Biochemistry and Biotechnology. 2016; 180: 544\u2013557.","DOI":"10.1007\/s12010-016-2115-7"},{"key":"ref152","doi-asserted-by":"publisher","unstructured":"Ning HQ, Lin H, Wang JX. Synergistic effects of endolysin Lysqdvp001 and \u03b5-poly-lysine in controlling Vibrio parahaemolyticus and its biofilms. International Journal of Food Microbiology. 2021; 343: 109112.","DOI":"10.1016\/j.ijfoodmicro.2021.109112"},{"key":"ref153","doi-asserted-by":"publisher","unstructured":"Kim M, Jo Y, Hwang YJ, Hong HW, Hong SS, Park K, et al. Phage-antibiotic synergy via delayed lysis. Applied and Environmental Microbiology. 2018; 84: e02085-18.","DOI":"10.1128\/AEM.02085-18"},{"key":"ref154","doi-asserted-by":"publisher","unstructured":"\u0141usiak-Szelachowska M, Weber-D\u0105browska B, G\u00f3rski A. Bacteriophages and lysins in biofilm control. Virologica Sinica. 2020; 35: 125\u2013133.","DOI":"10.1007\/s12250-019-00192-3"},{"key":"ref155","doi-asserted-by":"publisher","unstructured":"Han H, Li X, Zhang T, Wang X, Zou J, Zhang C, et al. Bioinformatic analyses of a potential Salmonella-virus-FelixO1 biocontrol phage BPS15S6 and the characterisation and anti-Enterobacteriaceae-pathogen activity of its endolysin LyS15S6. Antonie Van Leeuwenhoek. 2019; 112: 1577\u20131592.","DOI":"10.1007\/s10482-019-01283-7"},{"key":"ref156","doi-asserted-by":"publisher","unstructured":"Olsen NMC, Thiran E, Hasler T, Vanzieleghem T, Belibasakis GN, Mahillon J, et al. Synergistic Removal of Static and Dynamic Staphylococcus aureus Biofilms by Combined Treatment with a Bacteriophage Endolysin and a Polysaccharide Depolymerase. Viruses. 2018; 10: 438.","DOI":"10.3390\/v10080438"},{"key":"ref157","doi-asserted-by":"publisher","unstructured":"Liu B, Guo Q, Li Z, Guo X, Liu X. Bacteriophage Endolysin: A Powerful Weapon to Control Bacterial Biofilms. The Protein Journal. 2023; 42: 463\u2013476.","DOI":"10.1007\/s10930-023-10139-z"},{"key":"ref158","doi-asserted-by":"publisher","unstructured":"Portilla S, Fern\u00e1ndez L, Guti\u00e9rrez D, Rodr\u00edguez A, Garc\u00eda P. Encapsulation of the Antistaphylococcal endolysin LysRODI in pH-sensitive liposomes. Antibiotics (Basel, Switzerland). 2020; 9: 242.","DOI":"10.3390\/antibiotics9050242"},{"key":"ref159","doi-asserted-by":"publisher","unstructured":"Bai J, Yang E, Chang PS, Ryu S. Preparation and characterization of endolysin-containing liposomes and evaluation of their antimicrobial activities against gram-negative bacteria. Enzyme and Microbial Technology. 2019; 128: 40\u201348.","DOI":"10.1016\/j.enzmictec.2019.05.006"},{"key":"ref160","doi-asserted-by":"publisher","unstructured":"Usmani SS, Bedi G, Samuel JS, Singh S, Kalra S, Kumar P, et al. THPdb: Database of FDA-approved peptide and protein therapeutics. PloS One. 2017; 12: e0181748.","DOI":"10.1371\/journal.pone.0181748"},{"key":"ref161","doi-asserted-by":"publisher","unstructured":"Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, et al. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Research. 2018; 46: D1074\u2013D1082.","DOI":"10.1093\/nar\/gkx1037"},{"key":"ref162","doi-asserted-by":"crossref","unstructured":"Labrou N. Therapeutic enzymes: function and clinical implications. Springer: Singapore. 2019.","DOI":"10.1007\/978-981-13-7709-9"},{"key":"ref163","unstructured":"World Health Organization. 2021 antibacterial agents in clinical and preclinical development: an overview and analysis. World Health Organization: Geneva. 2022."},{"key":"ref164","doi-asserted-by":"publisher","unstructured":"Lu TK, Collins JJ. Dispersing biofilms with engineered enzymatic bacteriophage. Proceedings of the National Academy of Sciences of the United States of America. 2007; 104: 11197\u201311202.","DOI":"10.1073\/pnas.0704624104"},{"key":"ref165","doi-asserted-by":"publisher","unstructured":"Tott\u00e9 JEE, van Doorn MB, Pasmans SGMA. Successful treatment of chronic Staphylococcus aureus-related dermatoses with the topical endolysin Staphefekt SA.100: A report of 3 cases. Case Reports in Dermatology. 2017; 9: 19\u201325.","DOI":"10.1159\/000473872"},{"key":"ref166","doi-asserted-by":"publisher","unstructured":"Guti\u00e9rrez D, Fern\u00e1ndez L, Rodr\u00edguez A, Garc\u00eda P. Are phage lytic proteins the secret weapon to kill Staphylococcus aureus? mBio. 2018; 9: e01923-17.","DOI":"10.1128\/mBio.01923-17"},{"key":"ref167","doi-asserted-by":"publisher","unstructured":"Jun SY, Jang IJ, Yoon S, Jang K, Yu KS, Cho JY, et al. Pharmacokinetics and tolerance of the phage endolysin-based candidate drug SAL200 after a single intravenous administration among healthy volunteers. Antimicrobial Agents and Chemotherapy. 2017; 61: e02629\u201316.","DOI":"10.1128\/AAC.02629-16"},{"key":"ref168","doi-asserted-by":"publisher","unstructured":"Jun SY, Jung GM, Yoon SJ, Oh MD, Choi YJ, Lee WJ, et al. Antibacterial properties of a pre-formulated recombinant phage endolysin, SAL-1. International Journal of Antimicrobial Agents. 2013; 41: 156\u2013161.","DOI":"10.1016\/j.ijantimicag.2012.10.011"},{"key":"ref169","doi-asserted-by":"publisher","unstructured":"McCarthy MW. Exebacase: A novel approach to the treatment of Staphylococcal infections. Drugs in R&D. 2022; 22: 113\u2013117.","DOI":"10.1007\/s40268-022-00383-6"},{"key":"ref170","doi-asserted-by":"publisher","unstructured":"Harhala MA, Gembara K, Nelson DC, Miernikiewicz P, D\u0105browska K. Immunogenicity of endolysin PlyC. Antibiotics (Basel, Switzerland). 2022; 11: 966.","DOI":"10.3390\/antibiotics11070966"},{"key":"ref171","doi-asserted-by":"publisher","unstructured":"Watson A, Oh JT, Sauve K, Bradford PA, Cassino C, Schuch R. Antimicrobial activity of Exebacase (Lysin CF-301) against the most common causes of infective endocarditis. Antimicrobial Agents and Chemotherapy. 2019; 63: e01078\u201319.","DOI":"10.1128\/AAC.01078-19"},{"key":"ref172","doi-asserted-by":"publisher","unstructured":"Karau MJ, Schmidt-Malan SM, Yan Q, Greenwood-Quaintance KE, Mandrekar J, Lehoux D, et al. Exebacase in addition to daptomycin is more active than daptomycin or Exebacase alone in methicillin-resistant Staphylococcus aureus osteomyelitis in rats. Antimicrobial Agents and Chemotherapy. 2019; 63: e01235-19.","DOI":"10.1128\/AAC.01235-19"},{"key":"ref173","doi-asserted-by":"publisher","unstructured":"Wojciechowska M. Endolysins and membrane-active peptides: innovative engineering strategies against Gram-negative bacteria. Frontiers in Microbiology. 2025; 16: 1603380.","DOI":"10.3389\/fmicb.2025.1603380"},{"key":"ref174","doi-asserted-by":"publisher","unstructured":"Ba\u0142dysz S, Nawrot R, Barylski J. \u201cTear down that wall\u201d-a critical evaluation of bioinformatic resources available for lysin researchers. Applied and Environmental Microbiology. 2024; 90: e0236123.","DOI":"10.1128\/aem.02361-23"},{"key":"ref175","doi-asserted-by":"publisher","unstructured":"Euler CW, Raz A, Hernandez A, Serrano A, Xu S, Andersson M, et al. PlyKp104, a novel phage lysin for the treatment of Klebsiella pneumoniae, Pseudomonas aeruginosa, and other Gram-negative ESKAPE pathogens. Antimicrobial Agents and Chemotherapy. 2023; 67: e0151922.","DOI":"10.1128\/aac.01519-22"},{"key":"ref176","doi-asserted-by":"publisher","unstructured":"Fern\u00e1ndez-Ruiz I, Coutinho FH, Rodriguez-Valera F. Thousands of novel endolysins discovered in uncultured phage genomes. Frontiers in Microbiology. 2018; 9: 1033.","DOI":"10.3389\/fmicb.2018.01033"},{"key":"ref177","doi-asserted-by":"publisher","unstructured":"Gontijo MTP, Teles MP, Vidigal PMP, Brocchi M. Expanding the database of signal-anchor-release domain endolysins through metagenomics. Probiotics and Antimicrobial Proteins. 2022; 14: 603\u2013612.","DOI":"10.1007\/s12602-022-09948-y"},{"key":"ref178","doi-asserted-by":"publisher","unstructured":"Ni P, Wang L, Deng B, Jiu S, Ma C, Zhang C, et al. Characterization of a lytic bacteriophage against Pseudomonas syringae pv. actinidiae and its endolysin. Viruses. 2021; 13: 631.","DOI":"10.3390\/v13040631"},{"key":"ref179","doi-asserted-by":"publisher","unstructured":"Li C, Nyaruaba R, Zhao X, Xue H, Yang H, Li Y, et al. LysP53 activity against Salmonella and its application in decontamination of Salmonella on fresh romaine lettuce. Applied Microbiology and Biotechnology. 2023; 107: 5403\u20135413.","DOI":"10.1007\/s00253-023-12666-2"},{"key":"ref180","doi-asserted-by":"publisher","unstructured":"Sisson HM, Jackson SA, Fagerlund RD, Warring SL, Fineran PC. Gram-negative endolysins: overcoming the outer membrane obstacle. Current Opinion in Microbiology. 2024; 78: 102433.","DOI":"10.1016\/j.mib.2024.102433"}],"container-title":["Frontiers in Bioscience-Elite"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.imrpress.com\/journal\/FBE\/18\/2\/10.31083\/FBE44070","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T12:02:46Z","timestamp":1783425766000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.imrpress.com\/journal\/FBE\/18\/2\/10.31083\/FBE44070"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,1]]},"references-count":180,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026]]}},"alternative-id":["S1945-0494(26)02953-0"],"URL":"https:\/\/doi.org\/10.31083\/fbe44070","relation":{},"ISSN":["1945-0494","1945-0508"],"issn-type":[{"value":"1945-0494","type":"print"},{"value":"1945-0508","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,1]]},"article-number":"44070"}}